Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Receivables (2017 - 2025)

Historic Receivables for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $33.6 million.

  • Puma Biotechnology's Receivables fell 3857.4% to $33.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.6 million, marking a year-over-year decrease of 3857.4%. This contributed to the annual value of $32.4 million for FY2024, which is 3355.02% down from last year.
  • Latest data reveals that Puma Biotechnology reported Receivables of $33.6 million as of Q3 2025, which was down 3857.4% from $26.1 million recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Receivables peaked at $54.6 million during Q3 2024, and registered a low of $23.8 million during Q3 2021.
  • In the last 5 years, Puma Biotechnology's Receivables had a median value of $30.5 million in 2021 and averaged $32.0 million.
  • Its Receivables has fluctuated over the past 5 years, first surged by 8530.59% in 2024, then crashed by 3857.4% in 2025.
  • Over the past 5 years, Puma Biotechnology's Receivables (Quarter) stood at $32.5 million in 2021, then grew by 24.05% to $40.4 million in 2022, then grew by 20.74% to $48.7 million in 2023, then plummeted by 33.55% to $32.4 million in 2024, then rose by 3.68% to $33.6 million in 2025.
  • Its Receivables stands at $33.6 million for Q3 2025, versus $26.1 million for Q2 2025 and $25.2 million for Q1 2025.